<DOC>
	<DOC>NCT00615017</DOC>
	<brief_summary>This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773) in adult patients with severe sepsis.</brief_summary>
	<brief_title>AZD9773 Dose Escalation Study</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<criteria>Clinical evidence of infection requiring treatment with parenteral antibiotics Patients must meet multiple Systemic Inflammatory Response Syndrome (SIRS) criteria Patients must meet criteria for cardiovascular and/or respiratory dysfunction Sepsis (infection plus SIRS criteria) must be present prior to organ dysfunction Moribund and death is considered imminent, or patient not expected to survive 90 days because of underlying medical condition, or classified as Do Not Resuscitate or Do Not Treat Patient cannot attain a MAP &gt;60 mmHg when measured via an arterial line and/or a Systolic Blood Pressure (SBP) &gt;80 mmHg in the presence of vasopressors and iv fluids for a period of ≥2 hours Receiving immunosuppressants, or high dose steroids within 2 months of provision of informed consent Any history of hypersensitivity reaction to sheep products, latex, papain or papaya, or chymopapain or previously administered antivenom manufactured using ovine serum, digoxin immune fab (DigiFab™ , DIGIBIND® ), crotalidae polyvalent immune fab (ovine) (CroFab™ ), or other sheep derived product. Treatment with anti TumorNecrosisFactor (antiTNF) antibodies within 8 weeks before provision of written informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Sepsis</keyword>
	<keyword>septic shock</keyword>
	<keyword>Systemic Inflammatory Response Syndrome</keyword>
</DOC>